Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) said its revenue at the end of the latest quarter were 20.01M%, up 0.7%% from a corresponding period a year earlier.
Since Aralez Pharmaceuticals Inc. incurred expenses of $9.27M to generate the revenue, its gross income in the quarter was $10.74M. After deducting other operating expenses such salaries from the gross income, it ended up with a net income that gave it EPS of $(0.48).
Recently, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) announced the results of the matters voted upon at the Company’s 2017 annual and special meeting (the “Meeting”) of the shareholders of the Company (the “Shareholders”) held earlier today.
Let?s look into the technical of the stock
The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
The reported EPS resulted from dividing the net income with the number of outstanding shares. Investors should keep in mind that Aralez Pharmaceuticals Inc. finished the quarter with diluted outstanding shares of 65.5M.
For the next quarter, though, the analysts on Wall Street are expecting EPS of $-0.34 from Aralez Pharmaceuticals Inc..
Aralez Pharmaceuticals Inc. finished the most recent quarter with a cash balance of 64.94M%. It generated net cash flow of $(15.07M) from operations, yielding free cash flow of $(17.22M) for the quarter.
With that, the company concluded the quarter with total assets worth $517.38M. It also reported total debt of -%, with the debt having increased/decreased by growing from the previous quarter. Aralez Pharmaceuticals Inc. booked total liabilities of $397.89M in the latest quarter.
Analysts who have commented on Aralez Pharmaceuticals Inc. so far have an average recommendation of Buy on its stock. What does that mean? A recommendation in the range of 1.00 ? 1.24 indicates that a stock is a BUY. A recommendation in the band of 1.75 ? 2.24 suggests a stock is a HOLD, and a recommendation in the range of 2.75 ? 3.00 implies a stock is a SELL. So that tells you the perception of Aralez Pharmaceuticals Inc. on Wall Street.
However, outside BUY, HOLD and SELL, other available analyst recommendations are OVERWEIGHT and UNDERWEIGHT, represented by numbers in the range of 1.25 ? 1.74 and 2.25 ? 2.74, respectively.
Analysts on the average are also predicting that shares of Aralez Pharmaceuticals Inc. will be trading at $5.25 in the next 12 months.